FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368366987> ?p ?o ?g. }

• W4368366987 endingPage "100524" @default.
• W4368366987 startingPage "100524" @default.
• W4368366987 abstract "Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world.To evaluate the association between recently advanced drugs and patient survival, survival data of 2078 patients with stage IV NSCLC from 1995 to 2022 were analyzed in the present study. The patients were classified into the following six groups in terms of the date of diagnosis: period A, 1995 to 1999; period B, 2000 to 2004; period C, 2005 to 2009; period D, 2010 to 2014; period E, 2015 to 2019; and period F, 2000 to 2022. They were further grouped in terms of EGFR mutation and ALK fusion.The median overall survival (mOS) times were 8.9, 11.0, 13.6, 17.9, and 25.2 months in periods A to E, respectively, and the mOS time was not reached in period F. This time was significantly longer in period E than in period D (25.2 versus 17.9 mo, p < 0.005). Moreover, the mOS times of patients with EGFR mutation, those with ALK fusion, and those without both alterations were significantly longer in period E than in period D (46.0 versus 32.0 mo, p < 0.005; not reached versus 36.2 mo, p = 0.018; 14.6 versus 11.7 mo, p < 0.005). The history of treatment with next-generation TKIs and ICIs was found to be associated with overall survival.The survival of patients with NSCLC was improved from period D to period E, regardless of the presence of driver gene alteration. We found that next-generation TKIs and ICIs may be associated with improvements in overall survival." @default.
• W4368366987 created "2023-05-05" @default.
• W4368366987 creator A5004541515 @default.
• W4368366987 creator A5014758837 @default.
• W4368366987 creator A5020979394 @default.
• W4368366987 creator A5023713698 @default.
• W4368366987 creator A5024109433 @default.
• W4368366987 creator A5043698933 @default.
• W4368366987 creator A5051355961 @default.
• W4368366987 creator A5056703048 @default.
• W4368366987 creator A5071587141 @default.
• W4368366987 creator A5078287634 @default.
• W4368366987 creator A5083962517 @default.
• W4368366987 date "2023-06-01" @default.
• W4368366987 modified "2023-09-27" @default.
• W4368366987 title "Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors" @default.
• W4368366987 cites W2065477010 @default.
• W4368366987 cites W2104347254 @default.
• W4368366987 cites W2125735484 @default.
• W4368366987 cites W2129360604 @default.
• W4368366987 cites W2132000516 @default.
• W4368366987 cites W2132157071 @default.
• W4368366987 cites W2156353875 @default.
• W4368366987 cites W2560717039 @default.
• W4368366987 cites W2567564314 @default.
• W4368366987 cites W2572174216 @default.
• W4368366987 cites W2924237217 @default.
• W4368366987 cites W2936974622 @default.
• W4368366987 cites W2946166987 @default.
• W4368366987 cites W2976744492 @default.
• W4368366987 cites W2990041408 @default.
• W4368366987 cites W3013058016 @default.
• W4368366987 cites W3031018272 @default.
• W4368366987 cites W3048896255 @default.
• W4368366987 cites W3081278682 @default.
• W4368366987 cites W3091399767 @default.
• W4368366987 cites W3110320999 @default.
• W4368366987 cites W3122627530 @default.
• W4368366987 cites W3211473910 @default.
• W4368366987 cites W4210782314 @default.
• W4368366987 cites W4214645406 @default.
• W4368366987 cites W4220990951 @default.
• W4368366987 cites W4249713788 @default.
• W4368366987 cites W4280533169 @default.
• W4368366987 cites W4318070818 @default.
• W4368366987 doi "https://doi.org/10.1016/j.jtocrr.2023.100524" @default.
• W4368366987 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37426307" @default.
• W4368366987 hasPublicationYear "2023" @default.
• W4368366987 type Work @default.
• W4368366987 citedByCount "0" @default.
• W4368366987 crossrefType "journal-article" @default.
• W4368366987 hasAuthorship W4368366987A5004541515 @default.
• W4368366987 hasAuthorship W4368366987A5014758837 @default.
• W4368366987 hasAuthorship W4368366987A5020979394 @default.
• W4368366987 hasAuthorship W4368366987A5023713698 @default.
• W4368366987 hasAuthorship W4368366987A5024109433 @default.
• W4368366987 hasAuthorship W4368366987A5043698933 @default.
• W4368366987 hasAuthorship W4368366987A5051355961 @default.
• W4368366987 hasAuthorship W4368366987A5056703048 @default.
• W4368366987 hasAuthorship W4368366987A5071587141 @default.
• W4368366987 hasAuthorship W4368366987A5078287634 @default.
• W4368366987 hasAuthorship W4368366987A5083962517 @default.
• W4368366987 hasBestOaLocation W43683669871 @default.
• W4368366987 hasConcept C121332964 @default.
• W4368366987 hasConcept C126322002 @default.
• W4368366987 hasConcept C143998085 @default.
• W4368366987 hasConcept C146357865 @default.
• W4368366987 hasConcept C151730666 @default.
• W4368366987 hasConcept C170493617 @default.
• W4368366987 hasConcept C24890656 @default.
• W4368366987 hasConcept C2781291010 @default.
• W4368366987 hasConcept C3019894029 @default.
• W4368366987 hasConcept C42362537 @default.
• W4368366987 hasConcept C71924100 @default.
• W4368366987 hasConcept C86803240 @default.
• W4368366987 hasConcept C90924648 @default.
• W4368366987 hasConceptScore W4368366987C121332964 @default.
• W4368366987 hasConceptScore W4368366987C126322002 @default.
• W4368366987 hasConceptScore W4368366987C143998085 @default.
• W4368366987 hasConceptScore W4368366987C146357865 @default.
• W4368366987 hasConceptScore W4368366987C151730666 @default.
• W4368366987 hasConceptScore W4368366987C170493617 @default.
• W4368366987 hasConceptScore W4368366987C24890656 @default.
• W4368366987 hasConceptScore W4368366987C2781291010 @default.
• W4368366987 hasConceptScore W4368366987C3019894029 @default.
• W4368366987 hasConceptScore W4368366987C42362537 @default.
• W4368366987 hasConceptScore W4368366987C71924100 @default.
• W4368366987 hasConceptScore W4368366987C86803240 @default.
• W4368366987 hasConceptScore W4368366987C90924648 @default.
• W4368366987 hasIssue "6" @default.
• W4368366987 hasLocation W43683669871 @default.
• W4368366987 hasLocation W43683669872 @default.
• W4368366987 hasLocation W43683669873 @default.
• W4368366987 hasOpenAccess W4368366987 @default.
• W4368366987 hasPrimaryLocation W43683669871 @default.
• W4368366987 hasRelatedWork W1922489046 @default.
• W4368366987 hasRelatedWork W2017990408 @default.
• W4368366987 hasRelatedWork W2029605690 @default.

• next